HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Bone Health · Osteoporosis Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Bone Health · Osteoporosis Therapeutic Area Assessment

5 signals · 3 insights · 25 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 61%

Evidence

33 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Bone Health · Osteoporosis integrates 5 signals, 3 executive insights, and 25 regulatory precedents from the Humanexa intelligence graph. 1 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 13, 2026

    FDA Approves Supplement for Alendronate Sodium by Rising

    The FDA has approved a supplemental application for Alendronate Sodium submitted by Rising.

    View detail
  2. signalJul 3, 2026

    FDA Grants AP Status for Alendronate Sodium ANDA206387

    The FDA has granted approval status (AP) for the ANDA206387 application for Alendronate Sodium submitted by IPCA Labs Ltd.

    View detail
  3. signalJun 27, 2026

    FDA Submission Update for Prolia (Denosumab) by Amgen

    Amgen has submitted a supplemental application for Prolia (denosumab) under BLA125320 with standard review priority.

    View detail
  4. signalJun 23, 2026

    FDA Grants AP Status for Teva's Risedronate Sodium Supplement

    Teva Pharmaceuticals has received an Abbreviated Approval (AP) for a supplement of Risedronate Sodium.

    View detail
  5. regulatoryJul 13, 2026

    FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

    Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alendronate Sodium; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  6. regulatoryJul 13, 2026

    FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alendronate Sodium; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  7. regulatoryJul 13, 2026

    FDA AP — ALENDRONATE SODIUM (SUPPL)

    Application ANDA075710. Sponsor: IMPAX LABS INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.

    View detail
  8. regulatoryJul 13, 2026

    FDA AP — ALENDRONATE SODIUM (SUPPL)

    Application ANDA076584. Sponsor: RISING. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.

    View detail
  9. insightJun 27, 2026

    Amgen's Prolia Submission Signals Potential Competitive Advantage in Osteoporosis Market

    The FDA's acceptance of Amgen's supplemental application for Prolia signifies potential label expansion, which could enhance its competitive positioning in the osteoporosis market. Portfolio teams must evaluate the implications of this development on market share relative to other osteoporosis treatments. Regulatory context from FDA (FDA AP — PROLIA (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (7 high-relevance).

    View detail
  10. insightJun 23, 2026

    Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    The FDA's grant of Abbreviated Approval status to Aurobindo Pharma for Risendronate Sodium signifies a new competitive entrant in the bisphosphonate market. This could impact pricing and market share for existing therapies, necessitating strategic adjustments by current market players. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (14 high-relevance).

    View detail
  11. insightJun 23, 2026

    Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market

    The FDA's grant of Abbreviated Approval for Teva's Risedronate Sodium supplement is significant as it strengthens Teva's competitive position in the osteoporosis market. Portfolio teams must evaluate the implications for market share and pricing strategies in response to this regulatory development. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 3 risk-calibrated assessments for portfolio review. 25 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 3 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

    66%

    Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alendronate Sodium; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    66%

    Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alendronate Sodium; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA AP — ALENDRONATE SODIUM (SUPPL)

    66%

    Application ANDA075710. Sponsor: IMPAX LABS INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — ALENDRONATE SODIUM (SUPPL)

    66%

    Application ANDA076584. Sponsor: RISING. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.

    Source: FDA

    View evidence

  • FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

    84%

    The FDA has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication.

    Source: FDA

    View evidence

  • FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    66%

    Application ANDA207549. Sponsor: AMNEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHYLPREDNISOLONE SODIUM SUCCINATE.

    Source: FDA

    View evidence

  • Amgen's Prolia Submission Signals Potential Competitive Advantage in Osteoporosis Market

    60%

    The FDA's acceptance of Amgen's supplemental application for Prolia signifies potential label expansion, which could enhance its competitive positioning in the osteoporosis market. Portfolio teams must evaluate the implications of this development on market share relative to other osteoporosis treatments. Regulatory context from FDA (FDA AP — PROLIA (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (7 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    69%

    The FDA's grant of Abbreviated Approval status to Aurobindo Pharma for Risendronate Sodium signifies a new competitive entrant in the bisphosphonate market. This could impact pricing and market share for existing therapies, necessitating strategic adjustments by current market players. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (14 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market

    55%

    The FDA's grant of Abbreviated Approval for Teva's Risedronate Sodium supplement is significant as it strengthens Teva's competitive position in the osteoporosis market. Portfolio teams must evaluate the implications for market share and pricing strategies in response to this regulatory development. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Supplement for Alendronate Sodium by Rising

    Regulatory Approval

  • FDA Grants AP Status for Alendronate Sodium ANDA206387

    Regulatory Approval

  • FDA Submission Update for Prolia (Denosumab) by Amgen

    Regulatory Approval

  • FDA Grants AP Status for Teva's Risedronate Sodium Supplement

    Regulatory Approval

  • Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status

    Regulatory Approval

Insights

  • Amgen's Prolia Submission Signals Potential Competitive Advantage in Osteoporosis Market

    Bone Health · Osteoporosis

  • Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    Bone Health · Bisphosphonate

  • Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market

    Osteoporosis · Bisphosphonate

Companies

  • Teva

    25 signals

  • Aurobindo Pharma

    29 signals

  • Amgen

    13 signals

Assets

  • Risendronate Sodium
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.